PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Clinical trials for PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) explained in plain language.

Never miss a new study

Get alerted when new PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) trials appear

Sign up with your email to follow new studies for PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Heart gene therapy trial aims to fix deadly rhythm disorder

Disease control Recruiting now

This early-stage trial tests a one-time gene therapy for people with a genetic heart condition that causes dangerous heart rhythms. The therapy delivers a working copy of the PKP2 gene to heart cells. The study involves 9 adults with an implanted defibrillator and frequent extra …

Matched conditions: PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Phase: PHASE1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control

Last updated May 19, 2026 11:47 UTC

PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM)

Get alerted when new PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY (PKP2-ACM) trials appear

Heart gene therapy trial aims to fix deadly rhythm disorder